TO STUDY THE ANTI-INFLAMMATORY AND IMMUNOMODULATORY EFFECTS OF SINAPIS NIGRA IN ALLERGIC RHINITIS USING CELL LINE STUDIES AND CLINICAL TRIAL

ANTI-INFLAMMATORY AND IMMUNOMODULATORY EFFECTS OF SINAPIS NIGRA IN ALLERGIC RHINITIS USING CELL LINE STUDIES AND CLINICAL TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109852

Enrollment

Registered

2026-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Sinapis Nigra: Sinapis Nigra 6C or Tincture 5drops twice daily. Control Intervention1: Homoeopathic Constitutional medicne: constitutional medicine given orally according to Homooepathi

Eligibility

Inclusion criteria

Inclusion criteria: Cases with clinical features of allergic rhinitis having raised IgE level above 100 Patients in the age-group of 15-65 years of both sexes.

Exclusion criteria

Exclusion criteria: Patients with other serious respiratory illness like pulmonary tuberculosis, cystic fibrosis, CA lung. Pregnant and lactating mother. Patients who are taking steroids and other medications for allergic rhinitis.

Design outcomes

Primary

Measure	Time frame
Anti-inflammatory and immunomodulatory effects of Sinapis Nigra using MTT assay and FACS.Identify the action of Sinapis nigra in allergic rhinitis, by analyzing cell viability and cytokine expression pathways.Timepoint: CELL LINE STUDY- 1 MONTH CLINICAL STUDY- 3 MONTHS	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Sreelakshmi Shankar

Government Homoeopathic Medical College,Kozhikode

drmansoorkr@gmail.com9249337799

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026